Trial Profile
A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Nov 2023
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms TRANSFORMS
- Sponsors Novartis; Novartis Pharma A.G.
- 13 Oct 2023 Results of pooled analysis (from studies ASCLEPIOS I/II for OFAand from FREEDOMS I, II and TRANSFORMS for FIN) assessing Indirect Treatment Comparison Methodologies to Differentiate the Efficacy of Ofatumumab and Other High Efficacy Therapies versus Orally Administered Disease Modifying Therapies for Relapsing Multiple Sclerosispresented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research
- 01 Nov 2021 Results of PSM-based ITC analysis from following clinical trials: EXPAND, INFORMS, FREEDOMS, FREEDOMS-II, TRANSFORMS, ASCLPEIOS-I and ASCLPEIOS-II published in the Current Medical Research and Opinion
- 19 Jun 2018 Results of a pooled analysis from FREEDOMS and TRANSFORMS trials presented at the 4th Congress of the European Academy of Neurology